SCHEMBL6507956

SCHEMBL6507956

Cc1cc(CC(N)=O)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.46
DAO P14920 1/20 0.46
HTT P42858 1/20 0.44
ALPL P05186 3/20 0.38
CSNK2A2 P19784 1/20 0.37
KDR P35968 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
CCNA2 P20248 2/20 0.36
CDK2 P24941 2/20 0.36
CCNA1 P78396 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12174907 0.82 HCAR2 (0.47) HCAR2DAOALPLCCNA2CDK2
SCHEMBL877436 0.82 HCAR2 (0.52) HCAR2DAOALPLCCNA2CDK2
Hydrochloric Acid SCHEMBL1371875 0.81 HCAR2 (0.50) HCAR2DAOALPLCCNA2CDK2
SCHEMBL3587984 0.78 KDM4E (0.48) HCAR2DAOALPLCCNA2CDK2
SCHEMBL12158535 0.78 HCAR2 (0.43) HCAR2DAOALPLCCNA2CDK2
SCHEMBL8720083 0.77 SMN1; SMN2 (0.51) HCAR2DAOPOLBKMT2ACYP2C9
SCHEMBL31498925 0.74 HCAR2 (0.43) HCAR2DAOHTTCCNA2CDK2
SCHEMBL12985517 0.73 HTT (0.48) HCAR2DAOHTTALPLCSNK2A2
SCHEMBL19334092 0.73 HCAR2 (0.39) HCAR2DAOALPLPOLBKMT2A
SCHEMBL3465530 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4316492-B1 COMBINATION OF A MULTIKINASE INHIBITOR WITH A PD-1/PD-L1 ANTIBODY AND USES THEREOF TRANSTHERA SCIENCES NANJING INC (CN) 2025-12-03 EP disclosed
US-11718620-B2 Method for treating a cancer mediated by abnormality of multi-kinases TRANSTHERA SCIENCES (NANJING), INC. (CN) 2023-08-08 US disclosed
CN-115698008-A Pyrazolo [1,5-a ] pyrimidine derivatives having multimodal activity against pain 埃斯特韦制药股份公司 2023-02-03 CN disclosed
EP-2627653-A1 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS Glaxo Group Limited (GB) 2013-08-21 EP disclosed
WO-2012049161-A1 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS GLAXO GROUP LIMITED (GB) 2012-04-19 WO disclosed
WO-2005092841-A1 COMPOUNDS HAVING BETA-AGONIST ACTIVITY PFIZER LIMITED (GB) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718620-B2 Method for treating a cancer mediated by abnormality of multi-kinases MAP3K1, MAP3K5, MAP3K2 HCAR2 3759/4885DAO 2261/4885HTT 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.